Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas
NCT ID: NCT02547350
Last Updated: 2015-09-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
200 participants
INTERVENTIONAL
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients
NCT02923557
Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients
NCT02740426
The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence
NCT03209206
Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma
NCT05979909
The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence
NCT03062059
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Blank control
do not use prophylactic intravesical chemotherapy
No interventions assigned to this group
single intravesical instillation
intravesical instillation within 24 hours postoperatively
pharmorubicin or pirarubicin
pharmorubicin 50mg pirarubicin 30mg
multiple intravesical instillation
intravesical instillation every 1 week for the first 2 months, then once a month for the rest 10 months
pharmorubicin or pirarubicin
pharmorubicin 50mg pirarubicin 30mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pharmorubicin or pirarubicin
pharmorubicin 50mg pirarubicin 30mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Treated with radical nephroureterectomy
Exclusion Criteria
2. Prior history of bladder or synchronous bladder cancer
3. Administration of neoadjuvant chemotherapy
4. Presence of severe complications.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xuesong Li
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xuesong Li
professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PIC-UTUC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.